CTN Bulletin logo
March 16, 2023  

REGISTER NOW! 2023 Annual CTN Steering Committee Meeting, April 24-26, 2023

NIDA SC Meeting logo

Registration is now open for this year’s CTN Annual Steering Committee Meeting, April 24-26, 2023!

The 2023 CTN Annual Steering Committee Meeting is being held in-person at the Bethesda North Marriott Hotel and Conference Center (book your reservation here!) in Rockville, Maryland, from April 24-26, 2023.

For those unable to attend in person, all plenary sessions and some ancillary sessions will be broadcast via Zoom. The level of interaction available virtually will vary by session.

Both in-person and virtual attendees will register on the Zoom Events platform:

  • If you have a Zoom account, please click "register with Zoom account."
  • If you do not have a Zoom account, click "register with email."

Both methods will give you the same virtual experience and will not affect in-person attendance!

The "Information" tab includes hotel, travel, agenda and other meeting details. More information will be added to this site as it becomes available. The “Frequently Asked Questions” guide at the bottom of this email has more information regarding meeting logistics, including how to change your registration type.

Important Links

Individuals with disabilities who need sign language interpreting and/or other reasonable accommodations to participate in this event, should contact Sean Randol at (240) 863-0507 or srandol@leedmci.com or through the Federal Relay (1-800-877-8339). Requests should be made at least five business days in advance of the event.

Please contact the LMCi Logistics Team at ctnsupport@leedmci.com with questions. We are excited about being back in person and look forward to seeing you at this important meeting!

CTN Trial Progress

GraphRandomizations for Active Studies as of the March 15 Trial Progress Report.

CTN-0080 - Enrolled 133

CTN-0098 - Enrolled 123

CTN-0099 - Enrolled 1428

CTN-0099-A-1 - Enrolled 96

Discontinuation -
Enrolled 128
Retention -
Enrolled 727

CTN-0101 - Enrolled 196

CTN-0107 - Enrolled 123

CTN-0108 - Enrolled 77

This project is supported by a grant from the National Institute on Drug Abuse to the University of Washington Additions, Drug & Alcohol Institute, but the information on this site has not been reviewed by NIDA and does not necessarily reflect the views of the Institute.

· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·

Upcoming & Recorded Webinars

Justine Welsh, MDTOMORROW!
CTN Youth SIG: Missing the Mark: Medication Access in Specialty Addiction Treatment Settings for Youth with Opioid Use Disorder

March 17, 2023 | 11am-12pm PT

Justine W. Welsh, MD, Associate Professor, Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine

The objectives of the presentation are to 1) Describe a decreasing trend in buprenorphine prescribing for youth with opioid use disorder (OUD) 2) Recognize attitudes/beliefs among addiction treatment providers towards medication for OUD in youth 3) Propose new areas of research to increase utilization of MOUD across treatment settings.

Join the Zoom session here

Eva Quirion NP PhDNortheast Node: Injectable XR Buprenorphine: A Better Mousetrap or a Paradigm Shift in MOUD?
April 6, 2023 | 12pm-1pm ET

Eva Quirion, NP, PhD, St. Joseph Healthcare, Bangor, ME
1.0 AMA PRA Category 1 CME available!

Join the CTN Northeast Node on April 6, 2023 (12pm-1pm ET) for the latest in their Science Series: Injectable XR Buprenorphine: A Better Mousetrap or a Paradigm Shift in MOUD? with Eva Quirion, NP, PhD

This presentation will explore the science behind extended release (XR) buprenorphine and field experiences in the use of XR buprenorphine in a primary care setting. This talk will also address ways to bring this medication to patients and if this treatment makes financial sense.

Join the Zoom session here


NIDA HIV Research Program: Substance Use and HIV LatencyJonathan Karn PhD
April 26, 1-2pm ET

Jonathan Karn, PhD, Professor & Chair of the Department of Molecular Biology & Microbiology at Case Western Reserve University School of Medicine

The NIDA HIV Research Program (HRP) is pleased to announce the next presentation in its Seminar Series: A vicious cycle: The impact of inflammation and substance use on the control of HIV latency in microglia by Dr. Jonathan Karn, Professor & Chair of the Department of Molecular Biology & Microbiology at Case Western Reserve University School of Medicine. Dr. Karn has been studying transcriptional control in HIV since the mid-1980s. His current research focuses on the impact of substance use on the regulation of HIV transcription and latency in microglial cells.

Register here to receive your link.


Ayana Jordan, MD, PhDRECORDING AVAILABLE: Cultural Considerations for Addiction Research: Looking to the Past to Inform the Future

The Office of Research Training, Diversity, and Disparities is offering a series titled Profiles of Excellence: Focus on Diversity.

This webinar, held on March 6, 2023 from 4-5pm EST, featured Ayana Jordan, MD, PhD, of NYU Grossman School of Medicine, talking about “Cultural Considerations for Addiction Research: Looking to the Past to Inform the Future.”

View the recording here. (Passcode: Yyr!6b?j)


· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·

Protocol Update: CTN-0139

CTN-0139 logoCTN-0139, the Collaborative Care for Polysubstance use in Primary Care Settings (Co-Care) Trial, is studying a collaborative care intervention for polysubstance use involving opioids and/or stimulants, in adult primary care patients. Collaborative care is a team-based approach to managing chronic conditions that has been effective for depression and other behavioral health conditions, and has the potential to transform the delivery of substance use treatment in primary care settings.

This HEAL-funded CTN trial will test the Co-Care model versus enhanced usual care to reduce substance use and improve substance use-related functioning. The study will be conducted at 5 primary care sites (FQHCs and FQHC look-alikes). A pilot study will launch in February 2024 at one site, and the main study will start in August 2024 at all sites.

The Lead Team is currently conducting site selection activities and will be scheduling interviews in the coming weeks. If you have clinics who may be interested in participating, please contact Jasmine Fernando Jasmine.Fernando@nyulangone.org.

The Lead Investigator is Jennifer McNeely, MD, MS from the NY Node, and Co-Lead Investigator is Jane Liebschutz, MD, MPH from the Appalachian Node. For more information, contact the Project Director, Rebecca Stone Rebecca.Stone@nyulangone.org.

New from the ATTC Network

ATTC logoThe Good, the Bad, and the Ugly of Good Samaritan Laws by Shane Reader, PhD. ATTC Messenger, March 2023.

ATTC's Pearls of Wisdom: Learning from Indigenous Ways of Knowing by Meg Schneider (National American Indian/Alaska Native ATTC) ATTC/NIATx Service Improvement Blog.

News from the New England Consortium Node

McLean/HMS Addictions Conference May 5-6, 2023: Keynote Address to be delivered by Kathleen Brady, MD, MPH, PI of the CTN Southern Consortium Node.

Gail D’Onofrio, MD, MS, received the "Recognizing Excellence Among Us: HEAL Director’s Awards for Excellence in Research."

Shelly Greenfield, MD, MPH, received the 2022 AAAP Founders’ Award for being an outstanding member of the community who works in the field of addiction and who has contributed significantly to the science, teaching, treatment or public policy in the addictions

David Fiellin, MD, received the 2023 James H. Tharp Award American Society of Addiction Medicine (ASAM) for contributions toward finding a solution to the problem of alcohol use disorder.

News from the Big South/West Node

TX SUS logoJoin the PIs of the CTN Big South/West Node at this year’s Texas Substance Use Symposium (TxSUS) for their workshop, Screening, Interventions, and Successful Collaborative Care Models for Primary Care.

TxSUS will be held at the Henry B. Gonzalez Convention Center in San Antonio, TX from March 27-28, 2023. The Big South/West workshop will be held on day 2 (March 28) from 9:30-11:30am (CST).

For more information and to register for the conference, visit the conference website.

· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·

New in the CTN Dissemination Library

Journal coversOptimizing Recruitment and Retention in Substance Use Disorder Research in Emergency Departments. Worth L, et al. West J Emerg Med 2023 (in press). CTN-0047

Repurposing Ketamine to Treat Cocaine Use Disorder: Integration of Artificial Intelligence-Based Prediction, Expert Evaluation, Clinical Corroboration, and Mechanism of Action Analyses. Gao X, et al. Addiction 2023 (in press). CTN-0114

Differential Symptom Weighting in Estimating Empirical Thresholds for Underlying PTSD Severity: Toward a “Platinum” Standard for Diagnosis? Morgan-Lopez A, et al. Int J Methods Psychiatr Res 2023;31963. CTN-0015

Estimating the Impact of Stimulant Use on Initiation of Buprenorphine and Extended-Release Naltrexone in Two Clinical Trials and Real-World Populations. Cook RR, et al. Addict Sci Clin Pract 2023;18:11. CTN-0051, CTN-0067

CTN Webinar: Research 101: Introduction to Clinical Trials: The Basics. Kim M & Vasquez M. Produced by the National Drug Abuse Treatment Clinical Trials Network’s Clinical Coordinating Center, March 3, 2023.

Risk of Experiencing an Overdose Event for Patients Undergoing Treatment with Medication for Opioid Use Disorder. Brandt L, et al. Am J Psychiatry 2023 (in press). CTN-0027, CTN-0030, CTN-0051

· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·

NIH Request for Information (RFI)

Inviting input on use of a term like "preaddiction" for identifying and intervening in substance misuse and mild/early-stage substance use disorder

Recently, the term "preaddiction" has been proposed as a way to: raise public awareness about potentially harmful patterns of substance use, spur greater utilization of screening and brief intervention in clinical settings, prevent overdose, and promote the development of new interventions for potentially clinically significant substance misuse and/or early-stage SUD.

This RFI seeks input from people with lived experience of substance use, medical and scientific research communities, and other interested parties regarding the use of a term like preaddiction for identifying and intervening in potentially clinically significant substance misuse and/or early-stage SUD within healthcare settings.

Input is sought both on the terminology to describe this concept and the concept itself.

Find out more here.

Upcoming Events

2023 NIDA International Forum (free)
June 8-9, 2023 | Virtual
The Forum research symposium, poster session, and network-building activities focus on the range and quality of drug use and addiction research conducted around the world. Participants meet talented colleagues and learn about drug use and addiction research and policy issues in other countries, as well as the NIDA-supported fellowships and other programs that can support international collaborations.

2023 College on Problems of Drug Dependence (CPDD) Scientific Meeting
June 17-21, 2023
CPDD provides a national and international forum for scientists of diverse backgrounds to advance the understanding of molecular-neurobiological aspects of addictive disorders and, by the application of new scientific knowledge, to improve and develop treatments utilizing novel behavioral and pharmacological therapies.

Find more upcoming events at the NIDA website.



Published by the CTN Dissemination Library of the Pacific Northwest Node
Addictions, Drug & Alcohol Institute, University of Washington

This project is supported by a grant from the National Institute on Drug Abuse to the University of Washington Addictions, Drug & Alcohol Institute, but the information on this site has not been reviewed by NIDA and does not necessarily reflect the views of the Institute.

Unsubscribe | Subscribe